🔥Telegram İfşa

Thank you to Pasquale Santangeli and his team at the Cleveland Clinic AFIC lab for fresh preclinical work with Corfigo's 14Fr percutaneous HeartPad using pericardial wire access. Very promising results!

Epicardial ablation evolution. From Heart Rhythm Society meeting 2023 to recent pre-clinical work at Cleveland Clinic we showed that the HeartPad worked well with percutaneous pericardial access and aggressive device downsizing. Was great to catch up with our team VT Symposium!

Continuing to showcase some aspects of Corfigo, Inc 's recent pre-clinical work with partners at Cleveland Clinic Heart, Vascular & Thoracic , led by Pasquale Santangeli . One of the best things about cryo for percutaneous epicardial ablation is cryoadhesion. Once the tissue-device interface drops below freezing, it

Great work by ⁦Ioan Liuba⁩ in collaboration with ⁦⁦Corfigo, Inc⁩ with a novel XLT liquid helium cryoablation epicardial device

Thanks once again to our colleagues at Cleveland Clinic for another successful #HRS2024! Here at our poster session on Friday with Pasquale Santangeli and Ioan Liuba. We look forward to the scientific publication and the next round of work!

We are excited to share that we are moving into our next pre-clinical phase - developing our all-in-one XLT cryoablation device, the HeartPad® Ribbon. This adjustable-length epicardial ablation device will ultimately be used to ablate cardiac tissue in open surgical and minimal

Efficacy of Balloon Expandable Extreme-Low Temperature Ventricular Epicardial Cryoablation: A Preclinical Proof of Concept Evaluation Cleveland Clinic Heart, Vascular & Thoracic Ioan Liuba Arwa Younis MD Oussama Wazni heartrhythmjournal.com/article/S1547-…

Check out this timely review article co-authored with Pasquale Santangeli currently in press during Sudden Cardiac Arrest Awareness month American College of Cardiology . The field of VT ablation needs to expand dramatically - see the estimated number of epicardial VT ablations we should be considering